Key result
Rivaroxaban demonstrated superior effectiveness compared to warfarin in reducing the risk of stroke, systemic embolism, and major bleeding events in patients with atrial fibrillation.
Why the study?
Oral anticoagulation is standard therapy to prevent thromboembolism in AF, but determining whether rivaroxaban or warfarin is more effective remains clinically important.
Does rivaroxaban reduce stroke and systemic embolism compared to warfarin in patients with atrial fibrillation?
Does rivaroxaban reduce stroke and systemic embolism compared to warfarin in patients with atrial fibrillation?
Rivaroxaban demonstrates superior effectiveness and safety compared to warfarin for the prevention of embolic events in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May favor rivaroxaban over warfarin in AF; leaves open prospective validation in Indonesian populations.
Atrial Fibrillation (AF) is one of the most common types of cardiac arrhythmias caused by abnormal electrical activity in the heart's atria. A study conducted in Indonesia on the urban population in Jakarta obtained an AF incidence rate of 0.2% with a male to female ratio of 3:2. Oral anticoagulant therapy is the standard therapy for AF to prevent stroke and systemic embolism. The most widely used oral anticoagulants are Vitamin K Antagonist (VKA) such as Warfarin and Direct Oral Anticoagulants such as Rivaroxaban. This literature author conducted to compare the effectiveness. Warfarin and Rivaroxaban in dealing with embolic events in AF patients to find out which type of anticoagulant should be used. The literature sources used were Pubmed, Google Scholar, Medline, Ebsco, Hindawi, Science Direct and Cochrane. Anticoagulants have been used to prevent embolic disease in AF patients and the drug classes used are DOAC and VKA. Based on a literature search it was found that Rivaroxaban can reduce the risk of stroke and systemic embolism as well as major bleeding events compared to Warfarin. Rivaroxaban has been shown to have superior effectiveness compared to warfarin and can be used as an alternative drug in treating embolic events in AF patients.
No takes yet. Share an insight, caveat, or question.
Filipo David Tamara (2023) conducted a review in Atrial Fibrillation. Rivaroxaban vs. Warfarin was evaluated on Embolic events (stroke and systemic embolism). Rivaroxaban demonstrated superior effectiveness compared to warfarin in reducing the risk of stroke, systemic embolism, and major bleeding events in patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: